{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:38:53Z","timestamp":1790699933724,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We evaluated gefapixant, a P2X3 receptor antagonist, in participants with recent-onset (\u2264\u200912\u00a0months) refractory chronic cough (RCC) or unexplained chronic cough (UCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants (\u2265\u200918\u00a0years of age;\u2009\u2265\u200940\u00a0mm on a 100-mm cough severity visual analog scale [VAS] at screening and randomization) with chronic cough for\u2009&lt;\u200912\u00a0months were enrolled in this phase 3b, double-blind, placebo-controlled, parallel group, multicenter study (NCT04193202). Participants were randomized 1:1 to gefapixant 45\u00a0mg BID or placebo for 12\u00a0weeks with a 2-week follow-up. The primary efficacy endpoint was change from baseline at Week 12 in Leicester Cough Questionnaire (LCQ) total score. Adverse events were monitored and evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 415 participants randomized and treated (mean age 52.5\u00a0years; median [range] duration 7.5 [1\u201312] months): 209 received placebo and 206 received gefapixant 45\u00a0mg BID. A statistically significant treatment difference of 0.75 (95% CI: 0.06, 1.44; <jats:italic>p<\/jats:italic>\u2009=\u20090.034) for gefapixant vs. placebo was observed for change from baseline in LCQ total score at Week 12. The most common AE was dysgeusia (32% gefapixant vs. 3% placebo participants); serious AEs were rare (1.5% gefapixant vs. 1.9% placebo participants).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Gefapixant 45\u00a0mg BID demonstrated significantly greater improvement in cough-specific health status from baseline compared to placebo, in participants with recent-onset chronic cough. The most common AEs were related to taste and serious AEs were rare.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00408-023-00606-w","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T19:02:47Z","timestamp":1678129367000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough"],"prefix":"10.1007","volume":"201","author":[{"given":"Lorcan","family":"McGarvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandel","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury Grigorievich","family":"Shvarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schelfhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Martin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Reyfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna Sadaf","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"10328","key":"606_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH et al (2023) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. The Lancet 399(10328):909\u2013923","journal-title":"The Lancet"},{"issue":"1","key":"606_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.anai.2022.05.003","volume":"130","author":"PV Dicpinigaitis","year":"2022","unstructured":"Dicpinigaitis PV, Birring SS, Blaiss M et al (2023) Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Ann Allergy Asthma Immunol 130(1):60\u201366","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"606_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1378\/chest.15-1496","volume":"149","author":"P Gibson","year":"2016","unstructured":"Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS (2016) Treatment of unexplained chronic cough: CHEST guideline and expert panel report. Chest 149(1):27\u201344","journal-title":"Chest"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","volume":"187","author":"AA Raj","year":"2009","unstructured":"Raj AA, Pavord DI, Birring SS (2009) Clinical cough IV:what is the minimal important difference for the leicester cough questionnaire? Handb Exp Pharmacol 187:311\u2013320","journal-title":"Handb Exp Pharmacol"},{"issue":"8","key":"606_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8(8):775\u2013785","journal-title":"Lancet Respir Med"},{"issue":"5","key":"606_CR6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1183\/09031936.00217813","volume":"44","author":"AH Morice","year":"2014","unstructured":"Morice AH, Jakes AD, Faruqi S et al (2014) A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. Eur Respir J 44(5):1149\u20131155","journal-title":"Eur Respir J"},{"issue":"9974","key":"606_CR7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K et al (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385(9974):1198\u20131205","journal-title":"Lancet"},{"issue":"3","key":"606_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/pupt.2002.0364","volume":"15","author":"R Eccles","year":"2002","unstructured":"Eccles R (2002) The powerful placebo in cough studies? Pulm Pharmacol Ther 15(3):303\u2013308","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"606_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00408-019-00305-5","volume":"198","author":"R Eccles","year":"2020","unstructured":"Eccles R (2020) The powerful placebo effect in cough: relevance to treatment and clinical trials. Lung 198(1):13\u201321","journal-title":"Lung"},{"issue":"3","key":"606_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1006\/pupt.2002.0365","volume":"15","author":"PC Lee","year":"2002","unstructured":"Lee PC, Cotterill-Jones C, Eccles R (2002) Voluntary control of cough. Pulm Pharmacol Ther 15(3):317\u2013320","journal-title":"Pulm Pharmacol Ther"},{"issue":"Suppl 3","key":"606_CR11","first-page":"40","volume":"21","author":"A del Cuvillo","year":"2011","unstructured":"del Cuvillo A, Sastre J, Bartra J et al (2011) Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol 21(Suppl 3):40\u201345","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"24","key":"606_CR12","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1113\/JP280220","volume":"598","author":"MJ Farrell","year":"2020","unstructured":"Farrell MJ, Bautista TG, Liang E, Azzollini D, Egan GF, Mazzone SB (2020) Evidence for multiple bulbar and higher brain circuits processing sensory inputs from the respiratory system in humans. J Physiol 598(24):5771\u20135787","journal-title":"J Physiol"},{"issue":"4","key":"606_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/02770900009055454","volume":"37","author":"DP Joyce","year":"2000","unstructured":"Joyce DP, Jackevicius C, Chapman KR, McIvor RA, Kesten S (2000) The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 37(4):303\u2013318","journal-title":"J Asthma"},{"issue":"8","key":"606_CR14","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1523\/JNEUROSCI.4597-10.2011","volume":"31","author":"SB Mazzone","year":"2011","unstructured":"Mazzone SB, Cole LJ, Ando A, Egan GF, Farrell MJ (2011) Investigation of the neural control of cough and cough suppression in humans using functional brain imaging. J Neurosci Official J Soc Neurosci 31(8):2948\u20132958","journal-title":"J Neurosci Official J Soc Neurosci"},{"issue":"9","key":"606_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1164\/rccm.201306-1079OC","volume":"188","author":"J Leech","year":"2013","unstructured":"Leech J, Mazzone SB, Farrell MJ (2013) Brain activity associated with placebo suppression of the urge-to-cough in humans. Am J Respir Crit Care Med 188(9):1069\u20131075","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00606-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-023-00606-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00606-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T16:02:57Z","timestamp":1681920177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-023-00606-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s00408-023-00606-w","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"2 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LPM has received grants and personal fees from Merck Sharp & Dohme; personal fees from Applied Clinical Intelligence; grants from Asthma UK, Northern Ireland Chest Heart and Stroke, NC3Rs, British Heart Foundation, and Chiesi; travel and subsistence for attendance at scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, and Chiesi; and advisory board or consultancy fees from Almirall, NAPP, GlaxoSmithKline, and Boehringer Ingelheim. MRS has received grants and personal fees from Merck & Co., Inc; is a consultant to Bayer, Bellus, and NeRRe Therapeutics; and has done clinical research with Bellus. YGS reports no conflicts. SL, WCW, PX, JS, CL, AMN, PAR, and ASA are current or former employees of Merck & Co., Inc., Rahway, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}